AI assistant
Moderna, Inc. — Director's Dealing 2024
Jun 15, 2024
30610_dirs_2024-06-14_25655728-e97b-4a92-93c3-c9a58e17d4b2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-06-12
Reporting Person: AFEYAN NOUBAR (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-12 | Common Stock | S | 700 | $142.9696 | Disposed | 2328315 | Direct |
| 2024-06-12 | Common Stock | S | 408 | $144.4619 | Disposed | 2327907 | Direct |
| 2024-06-12 | Common Stock | S | 1263 | $145.5748 | Disposed | 2326644 | Direct |
| 2024-06-12 | Common Stock | S | 3031 | $146.5483 | Disposed | 2323613 | Direct |
| 2024-06-12 | Common Stock | S | 6397 | $147.5498 | Disposed | 2317216 | Direct |
| 2024-06-12 | Common Stock | S | 1601 | $148.613 | Disposed | 2315615 | Direct |
| 2024-06-12 | Common Stock | S | 1400 | $149.3927 | Disposed | 2314215 | Direct |
| 2024-06-12 | Common Stock | S | 200 | $150.24 | Disposed | 2314015 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3880328 | Indirect |
| Common Stock | 747897 | Indirect |
| Common Stock | 3924 | Indirect |
Footnotes
F1: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.49 to $143.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Includes shares received in distributions-in-kind from Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") made prior to the filing of this report in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.04 to $145.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.04 to $146.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.04 to $147.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.05 to $148.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.08 to $149.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.15 to $149.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.21 to $150.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F11: The shares are held directly by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F12: The shares are held directly by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F13: The shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.